Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
News Jan 14, 2014
Dr. Gilham was Chief Executive Officer of Axis-Shield plc, the in vitro diagnostics company acquired by Alere in November 2011 for £235 million. Before its sale to Alere, Axis-Shield’s revenues rose above £100 million and the Company issued a maiden dividend. Prior to joining Axis-Shield, Dr. Gilham held international general management, marketing, business development and R&D positions with GSK, Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.
Dr. Gilham is also currently non-executive Chairman of Multiplicom, focused on the development and commercialization of innovative molecular genetic tests; and Biosurfit SA, focused on development and commercialization of point-of-care diagnostic products.
Dr. Darrin Disley, CEO of Horizon, commenting on the announcement, said: “We are delighted that Ian has decided to accept the position of Chairman of the Board on a permanent basis. As interim Chairman he has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organization.”
Dr. Gilham added: “I believe Horizon Discovery is one of the World’s most innovative and promising life science organizations and I am very excited to continue to support the Company as Chairman. I am looking forward to working with the team during the next stages of the Company’s growth and development.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.